- Home
- APG vs EXEL Comparison
APG vs EXEL Comparison
Compare APG & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APG
- EXEL
- Stock Information
- Founded
- APG 1926
- EXEL 1994
- Country
- APG United States
- EXEL United States
- Employees
- APG N/A
- EXEL N/A
- Industry
- APG Engineering & Construction
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- APG Consumer Discretionary
- EXEL Health Care
- Exchange
- APG Nasdaq
- EXEL Nasdaq
- Market Cap
- APG 9.8B
- EXEL 11.3B
- IPO Year
- APG N/A
- EXEL 2000
- Fundamental
- Price
- APG $34.02
- EXEL $46.20
- Analyst Decision
- APG Strong Buy
- EXEL Buy
- Analyst Count
- APG 9
- EXEL 18
- Target Price
- APG $49.88
- EXEL $43.00
- AVG Volume (30 Days)
- APG 6.1M
- EXEL 3.6M
- Earning Date
- APG 07-31-2025
- EXEL 08-05-2025
- Dividend Yield
- APG N/A
- EXEL N/A
- EPS Growth
- APG N/A
- EXEL 237.58
- EPS
- APG 0.34
- EXEL 2.20
- Revenue
- APG $7,136,000,000.00
- EXEL $2,298,922,000.00
- Revenue This Year
- APG $8.12
- EXEL $9.37
- Revenue Next Year
- APG $5.31
- EXEL $11.05
- P/E Ratio
- APG $100.80
- EXEL $20.94
- Revenue Growth
- APG 3.20
- EXEL 24.49
- 52 Week Low
- APG $20.50
- EXEL $21.82
- 52 Week High
- APG $34.63
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- APG 68.59
- EXEL 59.21
- Support Level
- APG $32.70
- EXEL $43.32
- Resistance Level
- APG $34.38
- EXEL $44.48
- Average True Range (ATR)
- APG 0.68
- EXEL 1.54
- MACD
- APG -0.08
- EXEL 0.12
- Stochastic Oscillator
- APG 89.49
- EXEL 47.90
About APG APi Group Corporation
APi Group Corp operates in two segments: Safety Services segment includes providing safety services in North America, Asia Pacific, and Europe, focusing on end-to-end integrated occupancy systems (fire protection solutions, Heating, Ventilation, and Air Conditioning and entry systems), including design, installation, inspection, and service of these integrated systems. These services are provided in commercial, education, healthcare, high tech, industrial, and special-hazard settings. Specialty Services segment includes providing a variety of infrastructure services and specialized industrial plant services, which include maintenance and repair of critical infrastructure such as underground electric, gas, water, sewer, and telecommunications infrastructure.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.